Moderna Files Q2 2024 10-Q
Ticker: MRNA · Form: 10-Q · Filed: 2024-08-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
Moderna's Q2 2024 10-Q is in: financials and operations updated.
AI Summary
Moderna, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and business operations for the second quarter of 2024. Key financial data and operational updates are presented, reflecting the company's ongoing activities in the biotechnology sector.
Why It Matters
This filing provides investors and analysts with the latest financial health and strategic direction of Moderna, a key player in mRNA technology and vaccine development.
Risk Assessment
Risk Level: medium — Biotechnology companies like Moderna face inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-08-01 — Filing Date (Shows when the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Moderna, Inc. (company) — Filer of the 10-Q
- 2024-06-30 (date) — End of the reporting period
- 2024-08-01 (date) — Date of filing
- 325 BINNEY STREET (location) — Company's business and mailing address
- CAMBRIDGE, MA (location) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 1, 2024.
What is Moderna, Inc.'s primary business classification?
Moderna, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is Moderna's business address?
Moderna's business address is 325 BINNEY STREET, CAMBRIDGE, MA 02142.
What was the previous company name for Moderna, Inc.?
The former company name for Moderna, Inc. was Moderna Therapeutics, Inc., with a date of name change on August 22, 2016.
From the Filing
0001682852-24-000046.txt : 20240801 0001682852-24-000046.hdr.sgml : 20240801 20240801160228 ACCESSION NUMBER: 0001682852-24-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 241166455 BUSINESS ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 325 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 10-Q 1 mrna-20240630.htm 10-Q mrna-20240630 false 2024 Q2 0001682852 December 31 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent 135 337 xbrli:shares iso4217:USD iso4217:USD xbrli:shares mrna:candidate mrna:developmentProgram mrna:product mrna:participant mrna:security mrna:campus utr:sqft mrna:numberOfExtensionPeriod mrna:numberOfBuilding mrna:claim xbrli:pure 0001682852 2024-01-01 2024-06-30 0001682852 2024-07-26 0001682852 2024-06-30 0001682852 2023-12-31 0001682852 mrna:ProductSalesMember 2024-04-01 2024-06-30 0001682852 mrna:ProductSalesMember 2023-04-01 2023-06-30 0001682852 mrna:ProductSalesMember 2024-01-01 2024-06-30 0001682852 mrna:ProductSalesMember 2023-01-01 2023-06-30 0001682852 us-gaap:ProductAndServiceOtherMember 2024-04-01 2024-06-30 0001682852 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0001682852 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-06-30 0001682852 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0001682852 2024-04-01 2024-06-30 0001682852 2023-04-01 2023-06-30 0001682852 2023-01-01 2023-06-30 0001682852 us-gaap:CommonStockMember 2024-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001682852 us-gaap:RetainedEarningsMember 2024-03-31 0001682852 2024-03-31 0001682852 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001682852 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001682852 us-gaap:CommonStockMember 2024-06-30 0001682852 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001682852 us-gaap:RetainedEarningsMember 2024-06-30 0001682852 us-gaap:CommonStockMember 2023-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001682852 us-gaap:RetainedEarningsMember 2023-03-31 0001682852 2023-03-31 0001682852 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001682852 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001682852 us-gaap:CommonStockMember 2023-06-30 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001682852 us-gaap:RetainedEarningsMember 2023-06-30 0001682852 2023-06-30 0001682852 us-gaap:CommonStockMember 2023-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 00016